Seres Therapeutics, Inc. (MCRB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.0000 |
| Open | 3.0200 |
| Bid | 3.0100 x 1400 |
| Ask | 3.4200 x 4000 |
| Day's Range | 2.9750 - 3.2150 |
| 52 Week Range | 2.9050 - 25.0550 |
| Volume | |
| Avg. Volume | 767,130 |
| Market Cap | 295.196M |
| Beta (5Y Monthly) | 3.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9440 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MCRB
Related Research
- Seres Therapeutics, Inc.Daily – Vickers Top Insider Picks for 03/08/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat3 months agoArgus Research
- GlobeNewswire
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinic
- Business Wire
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass., May 22, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can produce fatty acids that disrupt the C. difficile lifecycle. These data were shared in oral and poster presentations at t
- Business Wire
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass., May 10, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the f
